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PhenothiazineMethicillin-resistant Staphylococcus aureus (MRSA) is currently one of the principal multiple drug resistant
bacterial pathogens causing serious infections, many of which are life-threatening. Consequently, new therapeutic
targets are required to combat such infections. In the current work, we explore the type 2 Nicotinamide adenine
dinucleotide reduced form (NADH) dehydrogenases (NDH-2s) as possible drug targets and look at the effects
of phenothiazines, known to inhibit NDH-2 from Mycobacterium tuberculosis. NDH-2s are monotopic
membrane proteins that catalyze the transfer of electrons from NADH via ﬂavin adenine dinucleotide (FAD) to
the quinone pool. They are required for maintaining the NADH/Nicotinamide adenine dinucleotide (NAD+)
redox balance and contribute indirectly to the generation of proton motive force. NDH-2s are not present in
mammals, but are the only form of respiratory NADH dehydrogenase in several pathogens, including S. aureus. In
this work, the two putative ndh genes present in the S. aureus genome were identiﬁed, cloned and expressed,
and the proteins were puriﬁed and characterized. Phenothiazines were shown to inhibit both of the S. aureus
NDH-2s with half maximal inhibitory concentration (IC50) values as low as 8 μM. However, evaluating the effects
of phenothiazines on whole cells of S. aureus was complicated by the fact that they are also acting as uncouplers
of oxidative phosphorylation. This article is part of a Special Issue entitled: 18th European Bioenergetic Conference.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Persistent infections involving slow-growing or non-growing bacteria
are hard to treat with antibiotics that target biosynthetic processes in
growing cells [1]. Consequently, the discoveries of newdrugs that disrupt
membrane function (including membrane potential and energy
metabolism) have been the focus of attention [2]. An example of
this is the diarylquinoline TMC207, which inhibits the membrane-
bound ATP synthase inMycobacterium tuberculosis [3], and is the ﬁrst an-
titubercular drug approved in 40 years (released by Johnson & Johnson).
Oxidative phosphorylation is driven by the transmembrane proton
motive force which is, in turn, generated by electron transfer through
the respiratory chain. The respiratory enzymes of human pathogens
present additional potential drug targets to disable their ability to
generate energy.
Bacteria contain three distinct families of respiratory NADH:quinone
oxidoreductases: Complex I, NDH-2, and a Na+-pumping Nqr complex
[4–7]. NDH-2s are composed of a single subunit of around 50 kDa
with a non-covalently bound FAD as a cofactor. They are monotopic
membrane proteins, being attached to the membrane throughopean Bioenergetic Conference.
1 217 244 3186.amphiphilic helices in the C-terminus [6,8]. NDH-2 catalyzes the trans-
fer of electrons fromNADH via FAD tomembrane-bound quinone, helps
tomaintain theNADH/NAD+ redox balance, and contributes indirectly to
the generation of proton motive force [9]. The crystal structure of a yeast
NDH-2 (Ndi1) was recently solved, demonstrating that the protein is a
homodimer with an amphiphilic membrane-anchor domain [6]. Since
NDH-2s are present only in bacteria and certain plant, fungal and proto-
zoan mitochondria, but not in mammals [10–13], they are an attractive
drug target and have been recognized as such forMycobacterium tubercu-
losis [14–17], Plasmodium falciparum [18] and Toxoplama gondii [13,19].
Particularly susceptible to this drug strategy should be those pathogenic
bacteria and parasites in which NDH-2 is the only respiratory NADH de-
hydrogenase present [13,18]. This includes Staphylococcus aureus.
Methicillin-resistant S. aureus (MRSA) is one of the principal multiple
drug resistant bacterial pathogens causing serious life-threatening
infections [20]. Very little is known about the biochemistry of the respira-
tory chain components of S. aureus. Analysis of the genome indicates that
two types of respiratory oxygen reductases are found in S. aureus cells,
one bd-type menaquinol oxidase and one heme-copper aa3-type
menaquinol oxidase. There is no bc1 complex in S. aureus and no cyto-
chrome c oxidase. L-lactate, succinate andNADHdehydrogenase activities
have been detected in S. aureus membranes [21–25] as well as ATP
synthase activity which can be inhibited by diarylquinolines related to
the anti-TB drug TMC207 [26]. S. aureus has no Complex I (type-I
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work that there are two functioning type-2 NADH:quinone oxidoreduc-
tases, NDH-2s, which are characterized as potential drug targets.
Phenothiazines,which are known to inhibit NDH-2 fromM. tuberculosis
and to have antitubercular activity [14,17,27], also have antibacterial
activity against MRSA [28]. It is demonstrated in the current work that
phenothiazines inhibit the S. aureus NDH-2s. However, we also show
that the phenothiazines, in addition to inhibiting the respiration of
S. aureus, are also uncouplers of oxidative phosphorylation.
2. Materials and methods
2.1. Sequence analysis
Sequences encoding NDH-2swere retrieved from the National Center
for Biotechnology Information (NCBI) database. The sequences were
aligned using MUSCLE [29]. Conserved residues were identiﬁed with
BIOEDIT. The C-terminal amphipathic helices were predicted using
PSIPRED (v3.0) [30].
2.1.1. Construction of expression plasmids
The gene encoding NdhF (SAB0804c) and NdhC (SAB0807) from
S. aureus RF122 strain (Dr. Stefan Monecke) was cloned into pET22b
(Apr, Novagen). To facilitate puriﬁcation, an 8His-tag was introduced
either in the N- or C-terminal of the ndhF and ndhC genes. The primers
contained theHis-tag andNdeI–HindIII restriction sites for the posterior
cloning in pET22b. NdhF-Fw (5′-GGAATTCCATATGCATCACCATCACCAT
CACCATCACAAAAACTTAGTTTTGTTAGGCGG-3′) and NdhF-Rv (5′-CCC
AAGCTTTTAACCATTATGATATTTATATAACCAAAGTACG-3′). NdhC-Fw
(5′-GGAATTCCATATGGCTCAAGATCGTAAAAAAGTACT-3′) and NdhC-
Rv (5′-CCCAAGCTTCTAGTGATGGTGATGGTGATGGTGGAATTTACCTTTT
TTGAATGCTAAAC-3′). For heterologous expression, the constructions
in pET22b were transformed into Escherichia coli C43 (DE3) strain
(Avidis, France), also containing pRARE for expression of rare codons
(Kmr) [31].
2.1.2. Cell growth, enzyme expression and puriﬁcation
E. coli C43 (DE3)was grown in LBmediumplus 100 μg/ml ampicillin
and 50 μg/ml kanamycin, at 37 °C and gene expression was induced by
the addition of 1 mM IPTG (isopropyl-D-thiogalactoside) when cells
reached an OD600 of ~0.7. All the puriﬁcation procedures were carried
out at 0–4 °C. Cells were harvested and resuspended in buffer A
(50 mM sodium phosphate, pH 7.5, 300 mM NaCl) with 5 mMMgSO4,
DNAse I and a protease inhibitor cocktail (Sigma). They were then
disrupted by passing twice through a microﬂuidizer at a pressure of
80,000psi. Cell extractwas centrifuged at 14,000×g for 10min to remove
the unbroken cells. Membranes were obtained after centrifugation at
230,000 ×g for 4 h. Pellets were resuspended in buffer A plus the pro-
tease inhibitor cocktail, and then solubilized by the addition of a
stock solution of 20% DDM (dodecyl-β-D-maltoside) dropwise to a
ﬁnal concentration of 1%. The solution was incubated at 4 °C for 2 h
with mild agitation. The suspension was cleared by centrifugation
at 230,000 ×g for 1 h. The supernatant was added to Ni-NTA resin
(Qiagen) pre-equilibrated with buffer A plus 0.05% DDM. The resin
was washed with buffer A plus 0.05% DDM and 10–20 mM histidine
and then the bound proteins were eluted with buffer A with 0.05%
DDM and 100 mM histidine. Fractions were concentrated by ﬁltration,
and then the histidine was removed by dialysis against buffer A plus
0.05% DDM. The puriﬁed protein could be stored frozen at −80 °C
after the addition of glycerol to a ﬁnal concentration of 10%.
2.2. Analytical methods
Theprotein puritywas evaluated by SDS-PAGEusing a 4–20%gradient
gel (Nusep). Protein concentration was determined using the BCA kit
(Thermo Scientiﬁc, Pierce Protein Research Products). The FAD contentof the isolated protein was determined spectroscopically with an Agilent
Technologies spectrophotometer (model 8453), using an extinction
coefﬁcient of 11.3 cm−1 mM−1 for the free oxidized ﬂavin at 450 nm
[32], after extraction from the protein by treatment of the sample
with 5% trichloroacetic acid [33].
2.3. Membrane preparations
Bacterial cells were grown in LB plus 30 mM Na-succinate for 2 or
8 h, as indicated. E. colimembrane preparations were carried out as de-
scribed above. S. aureusmembranes were obtained by incubating cells
with lysostaphin for 2 h at 37 °C and then passing them twice through
a microﬂuidizer at a pressure of 80,000 psi. The cell extract was centri-
fuged at 14,000 ×g for 10min to remove the unbroken cells. Membranes
were obtained by centrifugation at 230,000 ×g for 4 h. Pelletswere resus-
pended in buffer A containing 10% glycerol to 30–40 mg/ml of protein
and the suspension was stored at −80 °C. The respiration rates are
expressed as μmol O2 mg protein−1 s−1.
2.4. Steady state enzymatic activity assays
2.4.1. Method I: NADH dehydrogenase activity
The rate of NADH oxidation was measured at 37 °C. The 200 μl
reaction mixture contained 50 mM sodium phosphate buffer,
pH 7.5, 50–300 mM NaCl, 0.05% DDM, 20 μM FAD, 125 μg/ml asolectin,
0–150 μM quinone and 1–3 μg of the puriﬁed NdhF or 0.06–0.2 μg
NdhC. The reaction was started with the addition of 25–250 μM NADH
(prepared freshly in buffer) and the reaction's progress was moni-
tored by the decrease in absorption of NADH at 340 nm using an
Agilent 8453 UV–vis spectrophotometer. The extinction coefﬁcient of
6.22 cm−1 mM−1 at 340 nm was used for the absorption of NADH.
2.4.2. Method II: Oxygen consumption
Oxygen concentration was monitored using a YSI model 53 oxygen
electrode (Yellow Springs Instrument Co., Yellow Springs, OH) equipped
with a temperature-controlled 1.8-ml electrode chamber at 37 °C. The re-
action mixture for this assay consisted of sodium phosphate buffer,
pH 7.5, 50–300 mM NaCl, 20 μM FAD and 200–400 μg/ml membranes
and diluted isolated NdhC (0.06–0.2 μg) or NdhF (1–3 μg) enzymes. The
concentration of oxygen in the air-saturated buffer at this temperature
was assumed to be 250 μM, and the reaction was initiated by injecting
200 μMNADH.
2.4.3. Determination of kinetic constants
Kinetic parameters were determined using nonlinear least square
analysis (Origin8.0) of the data ﬁtted to the Michaelis–Menten rate
equation (v = Vmax(S) / (Km + S)), where v is the velocity, Vmax is the
maximum velocity, S is the substrate concentration and Km is the
Michaelis–Menten constant. The enzyme rates are expressed as
kcat, mol NADH oxidized or mol O2 (mol enzyme)−1 s−1. For testing
inhibitors, the enzyme, in the presence of the quinone substrate (soluble
analogues or membrane bound) was incubated in the reaction mix with
different concentrations of the inhibitors for 3min before NADHaddition.
2.5. Membrane potential measurements
The transmembrane electrical potential (inside negative) was deter-
mined by the quenching of the potential-sensitive ﬂuorescent probe
3,3′-dipropylthiodicarbocyanine (DisC3(5)). This lipophilic cationic
dye accumulates according to the Nernst equationwith high concentra-
tions in the electrically negative phase. At high concentrations, the dye
aggregates and the normal ﬂuorescence are quenched [34,35]. Collapse
of the membrane potential reverses the process and the ﬂuorescence
increases.
To perform this assay, cells of Newman strain [36] were grown for
2 h in LB and diluted to an OD600 nm of 0.3 in LB plus 10 mM glucose.
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suspension as indicated. Changes in ﬂuorescence due to the disruption of
the Δψ were continuously monitored with a ﬂuorescence spectropho-
tometer (Cary Eclipse, Agilent Technologies) employing an excitation
wavelength of 643 nm and an emission wavelength of 666 nm at 30 °C.
The magnitude of the Δψwas not quantiﬁed.
2.6. Drug susceptibility determination
The minimum inhibitory concentration (MIC) of phenothiazines on
the growth of S. aureus was determined by starting with an overnight
culture grown in LBmedium, diluted to an OD600 nm of 0.005, and incu-
bated for 20 h in the presence of the drugs inmicroliter plates (200 μl of
LB medium in 360 μl wells). The MIC reported is the lowest concentra-
tion of the phenothiazine that yields no visible growth after incubation
at 37 °C, 200 rpm for 20 h.
2.7. ATP/ADP determination
S. aureus cells (Newman strain)were grown for 2 h in LB and concen-
trated in the same medium to an OD600 nm of 2. Different concentrations
of TZ, as indicated, were added and the ATP/ADP ratios were determined
after 10 and 60 min of incubation at 37 °C, 200 rpm. ATP and ADP were
extracted from 50 μl cell suspension by adding trichloroacetic acid
(TCA) to a ﬁnal concentration of 0.5%. After 5 min, TAE (Tris–acetic
acid–EDTA) buffer was added to neutralize the pH by diluting the sample
5-fold. The cell content of ATP and ADP was measured according to the
manufacturer's protocol (ADP/ATP Ratio Assay Kit, catalogue number:
ab65313; Abcam).
2.8. Quinone extraction and analysis
The type and amount of quinone present in membranes of E. coli
GNB10608 (MG1655 ndh::FRT nuoA::FRT) strain [37] and in the puriﬁed
NDH-2s were determined by quinone extraction followed by reversed
phase HPLC analysis. 10 and 30 nmol of NdhC and NdhF puriﬁed
enzymes, together with 10 nmol of ubiquinone-10 (Q10) as an internal
standard, were extracted with 3 ml of 6:4 methanol:petroleum ether by
vortexing vigorously for 1 min (3 times). The mixture was allowed to
sit for 10 min before vortexing again for an additional min, followed by
centrifuging at 3000 rpm for 10 min. The pellet of 100 ml cell culture
was resuspended with 3.3 ml water and extracted with 16.8 ml of 6:4
methanol:petroleum ether by vortexing vigorously for 1 min (3 times).
Themixturewas allowed to sit for 2 h before vortexing again for an addi-
tional min, followed by centrifuging at 3000 rpm for 10 min.
The upper organic layer was removed to a fresh ﬂask, and the
remaining mixture was subjected to further extraction two more times
with 10 min incubation each. The organic phase was then evaporated
under a nitrogen stream, and the dried, oily residue was re-dissolved in
4:3:3 ethanol:methanol:acetonitrile. The extracted quinones were ana-
lyzed using a reversed phase Microsorb-MV 100-5 C18 HPLC column
(Varian, Palo Alto, CA) on a Beckman System Gold HPLC system ﬁtted
with a diode array detector, and monitored at 278 nm. The mobile
phase was 4:3:3 ethanol:methanol:acetonitrile. The type of quinone
present in the membranes was determined based on the elution of
quinone standards. The amounts were calculated from the ratio of
the peak areas.
2.9. Inverted membrane vesicles (IMVs)
IMVs of E. coli were prepared by three passages through a pre-
cooled French pressure cell at 20,000 psi. The lysate was centrifuged
at 14,000 ×g at 4 °C for 20 min to remove unbroken cells. The super-
natant was centrifuged at 370,000 ×g at 4 °C for 1 h and the pellet
consisting of the IMVs was washed with 50 mM MOPS-KOH
(pH 7.5), 2 mM MgCl2. After the second centrifugation step, themembranes were resuspended in 50 mM MOPS-KOH (pH 7.5),
2 mM MgCl2, 10% glycerol and stored at−80 °C.
2.9.1. Assay for ATP or succinate-driven proton translocation
Proton translocation into IMVs of E. coliwasmeasured by a decrease
of 9-amino-6-chloro-2-methoxyacridine (ACMA) ﬂuorescence. The
excitation and emissionwavelengths were 410 nmand 480 nm, respec-
tively. IMVs (0.1 mg/ml membrane protein) were preincubated at 37 °C
in 10 mM HEPES–KOH (pH 7.5), 100 mM KCl, 5 mMMgCl2 containing
2 μMACMA and the baseline was monitored for a fewminutes. The reac-
tion was then started by adding 1mMATP or 5 mM succinate. When the
signal was stabilized, different TZ concentrations were added.
2.9.2. Determination of transmembrane Δψ
The Δψ-sensitive ﬂuorophore Oxonol VI 1,5-Bis(5-oxo-3-
propylisoxazol-4-yl)pentamethine oxonol was used to determine if TZ
was able to dissipate the membrane potential in IMVs. E. coli IMVs
(0.1 mg/ml membrane protein) were added to the assay buffer; 10 mM
MOPS-KOH pH 7.5, 2 mMMgCl2, 2 μM Oxonol VI. After a few seconds,
0.5 mM NADH was added to initiate respiration-dependent generation
of Δψ (positive inside) and the resultant quenching of Oxonol VI ﬂuores-
cence was monitored at 37 °C. The emission and excitation wavelengths
were 599 nm and 634 nm, respectively. Uncoupling effect was estimated
on the basis of its ability to dissipate the established Δψ, recorded as a
dequenching of the ﬂuorescence signal.
3. Results
3.1. Sequence analysis
Inspection of the genome of the S. aureus RF122 strain [38] indicates
the presence of genes for succinate and malate dehydrogenases, two
types of menaquinol oxidases (aa3- and bd-type respiratory oxygen
reductases) and a nitrate reductase. There are no operons encoding for
either Complex I (the energy-coupled NADH:quinone oxidoreductase)
or Complex III (the quinone:cytochrome c oxidoreductase or bc1 com-
plex). NDH-2s have a very low sequence identity among each other,
and are, therefore, difﬁcult to reliably identify by amino acid sequence
analysis alone. Enzymological characterization is always necessary.
NDH-2s are characterized by the presence of (1) two GXGXXG motifs
that are present at the binding sites for adenine dinucleotides [39,40];
and (2) one or two predicted amphipathic helices at the C-terminus [6,
8]. Two candidate genes meet these criteria in the S. aureus genome
and both genes are shown in this work to encode authentic NDH-2s.
They will be referred to as ndhF, encoding the protein NdhF (NCBI gi:
3793682; SAB0804c) and ndhC, encoding the protein NdhC (NCBI gi:
3793685; SAB0807). NdhF and NdhC have a sequence similarity of 45%.
Both NdhF and NdhC contain the two conserved GXGXXG motifs. NdhF
has the ﬁrst motif starting at amino acid 8 and the second motif starting
at amino acid 147, and NdhC has the ﬁrst motif at amino acid 12 and the
second motif at amino acid 165. By using the PSIPRED (v3.0) software,
one C-terminal amphipathic helix was predicted for NdhF, extended
from amino acid 336 to 352 and two C-terminal amphipathic helices for
NdhC, one extending from amino acid 372 to 390 and the other from
amino acid 393 to398.
3.1.1. Gene expression and protein puriﬁcation
The cloned ndhF and ndhC genes were expressed heterologously in
E. coli C43(DE3). Both C- and N-terminus 8His-tag constructions were
made for each, but the NdhF protein was obtained only with the
N-terminal His-tag, whereas NdhC protein was obtained only with the
C-terminal His-tag.
The purity and size of the isolated proteins were analyzed by SDS-
PAGE (Fig. 1A). Both NdhF (Fig. 1A, lane 1) and NdhC (Fig. 1A, lane 2)
run near their predicted molecular weights of ~40 kDa. The UV–visible
spectra of the air-oxidized NdhF and NdhC proteins (Fig. 1B and C)
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Fig. 1. SDS-PAGE and UV–visible spectra of S. aureus NDH-2s expressed in E. coli.
(A) Coomassie Brilliant Blue staining of ~5 μg NdhF (lane 1) and NdhC (lane 2) proteins.
(B) NdhF exhibits peaks for the oxidized FAD at 375 nm, 455 nm and 550 nm and
(C) NdhC exhibits a typical UV–visible absorption spectrum of a ﬂavoprotein, with
characteristic peaks at 375 nm and 450 nm for the oxidized FAD.
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at 465 nm indicating that the cofactor is in an apolar environment in each
protein [41]. The spectrumofNdhC is typical forﬂavoproteinswith a peak
around 450 nm [42]. The spectrum NdhF at pH 7.5 shows an additional
broad absorbance centered at about 550 nm (Fig. 1B). The additional
absorption band results in a brick-red color of the solution of NdhF, com-
pared to the typical yellow color ofﬂavoproteins (includingNdhC). As the
solution of NdhF is made more acidic, down to pH 5, the peak at 550 nm
disappears, the color changes to yellow, and the major peak shifts from
452 nm to 445 nm (Fig. S1).
Precipitation of each protein with 5% tricholoracetic acid leaves
the FAD cofactor in solution, demonstrating that it is not covalently
bound [43]. The amount of ﬂavin bound to the recombinant NdhF pro-
tein was calculated to be 0.5 mol FAD/mol protein, and for NdhC was
0.25mol FAD/mol protein. FAD loss is a common issue for ﬂavoproteins
that are heterologously expressed [44–46]. Additionally, the quinone
content of NdhC and NdhF was analyzed by HPLC, and was always
less than 0.03 mol quinone/mol protein.Q8 DMN Q1 DUQ MD DQ Q2
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Fig. 2. Quinone-dependent enzyme activity of the S. aureus NDH-2s. (A) NdhF and (B) NdhC en
ferent soluble quinones or 220 μg/ml E. coliΔnuoΔndhmembranes plus 100 μMNADH forNdhC
and with Q1 is 2505 ± 215 NADH s−1 (100%) for NdhC, and all activities are expressed as the
experiments.3.2. Enzymatic characterization
The NADH:quinone oxidoreductase activities of the puriﬁed NdhF
and NdhC proteins were examined with 50 μM of several soluble qui-
nones as oxidants: menadione (MD), duroquinone (DQ), ubiquinone-
1 (Q1), ubiquinone-2 (Q2), decylubiquinone (DUQ) and 2,3-dimethyl
naphthoquinone (DMN) (Figs. 2 and S2). Since both proteins produced
in E. coli have sub-stoichiometric amounts of FAD, the assays were per-
formed in the presence of 20 μMFAD in the reactionmix. The activity of
both the enzymes increased signiﬁcantly when FAD as well as a lipid
mixture (125 μg/ml asolectin) were added to the reaction. The increase
of the speciﬁc activity corresponds roughly to full incorporation of
the lost FAD cofactor. The addition of FAD or lipids separately does
not increase the enzyme activity (395 ± 24 NADH s−1 for NdhC and
134 ± 12 NADH s−1 for NdhF), but when both lipids and FAD are
added enzyme activity increases by an amount consistent with full incor-
poration of FAD into the apo-enzymes present (1500± 85 NADH s−1 for
NdhC and 240 ± 17 NADH s−1 for NdhF). The assay buffer also contains
detergent (0.05% DDM) since both NdhC and NdhF are membrane pro-
teins. In addition, the NaCl concentration is important both for maximal
protein activity and stability. NdhC is unstable at 37 °C in buffer contain-
ing less than 125 mM NaCl and in the absence of lipids. On the other
hand, NdhF activity was optimal at lower concentrations of NaCl
(50–100 mM) (Table 1).
The natural oxidant of both NdhF and NdhC is menaquinone in the
S. aureus membrane [47]. In order to assay the activities of these
enzymes under more native-like conditions, a protocol was devised to
reconstitute the puriﬁed enzymes with E. coli membranes which lack
endogenous NADH oxidase activity. E. coli membranes were isolated
from a strain which lacks both NDH-2 and Complex I (Δndh Δnuo)
[37]. The quinone content of these membranes was determined by qui-
none extraction andHPLC analysis. Themembranes used for these exper-
imentswere fromcells grownunder conditionswhere themajor quinone
present is ubiquinone-8 (Q8) (Fig. S3A). This result is consistentwithpre-
vious studies [48] (Fig. S3B). NADH oxidase activity of the Δndh Δnuo
membranes is negligible, measured either by the oxidation of NADH or
oxygen utilization. However, under the same conditions in the presence
of 10 mM Na-succinate as electron donor, substantial oxygen utilization
is observed (207 ± 12 μmol O2 mg−1 protein s−1). By the addition of a
sufﬁcient amount of E. coli membranes and by inclusion of FAD in the
assay buffer, the maximum activities of the S. aureus NDH-2 enzymes
were determined using Q8 as the electron acceptor. In Fig. 2, the speciﬁc
activities of both enzymes are shown to be in the same range when the
long chain quinone is used as the electron acceptor as when using the
soluble quinone analogues. The NADH oxidation activities are increased
signiﬁcantly in the presence of exogenously added FAD, similar to what
is observed when phospholipids are added to the assays with solubleQ8 DMN Q1 DUQ MD DQ Q2
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zyme activities were measured at 37 °C with 20 μM FAD, 125 μg/ml asolectin, 50 μM dif-
and 300 μMforNdhF. ActivitymeasuredwithDUQ is 320±30NADH s−1 (100%) forNdhF
percent relative to these values. Data are expressed as average ± SD of four independent
Table 1
Kinetic parameters of the two NDH-2s present in S. aureus.
kcat (NADH s−1)a Km NADH (μM) Km DMN (μM) Preferred NaCl
concentration (mM)
NdhC 1500 ± 85 35 ± 2 37.5 ± 4 125–300
NdhF 240 ± 17 154 ± 10 29.7 ± 3 50–100
Data are expressed as average ± SD of at least three independent experiments.
a Enzyme activity was measured at 37 °C in the presence of 125 μg/ml asolectin, 20 μM
FAD, 50 μM DMN and 0.05% DDM plus 100 μM NADH for NdhC and 300 μM for NdhF,
respectively.
Table 3
IC50 values of phenothiazine compounds for the inhibition of NdhC and NdhF in vitro.
Compound Structure NDH-2 + Q8 IC50 (μM)a
Chlorpromazine
(CPZ)
NdhC 17 ± 2.5
NdhF 27.5 ± 3.5
Triﬂuoperazine
(TPZ)
NdhC 26.5 ± 3
NdhF ≫100 μM
Thioridazine
(TZ)
NdhC 7.9 ± 1
NdhF 13.5 ± 1.5
Data are expressed as average ± SD of at least three independent experiments.
a Enzyme activitywasmeasured at 37 °C in the presence of 220 μg/ml E. coliΔnuoΔndh
membranes and 20 μM FAD.
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obtained by monitoring either the oxidation of NADH spectrophotomet-
rically or by measuring oxygen uptake using the oxygraph (corrected for
2 NADH oxidized per O2 reduced). The data show that the isolated
enzymes are competent to bind to the membrane and rapidly reduce a
membrane-conﬁned long chain quinone, and that both of the S. aureus
NDH-2 enzymes canuse either ubiquinones ormenaquinones as electron
acceptors.
For convenience, further steady state kinetics characterization was
performed using the soluble analogue DMN (Table 1 and Fig. S2). The
kcat at 37 °C for the recombinant NdhF is 1500 ± 85 NADH s−1 and
for NdhC is 240 ± 17 NADH s−1 (Table 1). The apparent Km values for
both NADH and DMN are in the micromolar range. NdhF has 4-fold
higher Km for NADH than NdhC, whereas the Km for DMN is about the
same for both NdhF and NdhC (Table 1). Concentrations N 250 μM
NADH inhibit the activity of NdhC. Neither of the S. aureus NDH-2s
catalyze the oxidation of NADPH and, under the conditions examined,
do not directly reduce O2 to generate reactive oxygen species.
3.3. Inhibition of the NDH-2 activity by phenothiazines
M. tuberculosis NDH-2 has been shown to be inhibited by phenothi-
azine [14,24]. However, the effects of phenothiazines on NDH-2s from
other pathogens have not been explored. The inhibitory effects of differ-
ent phenothiazine compounds on the enzyme activities of the two pu-
riﬁed S. aureus NDH-2s were examined using either DMN as the
electron acceptor in detergent solutions, or by coupling the enzymes
to the E. coli respiratory chain in the absence of detergents (Tables 2
and 3). The phenothiazines were found to be more potent inhibitors
when assaying the enzymes using E. coli membranes (Table 2), and
this assay was used for most experiments (Table 3).
Three different phenothiazines were examined: TPZ, TZ and CPZ (see
Table 3). Each was able to inhibit at least one of the two S. aureus NDH-2
enzymes, with 50% inhibition (IC50) in the 10–30 μMrange (Table 3). De-
spite the apparent similarities of these two enzymes, theremust be subtle
structural differences leading to differences in theway the inhibitors bind
to the proteins. The best of the three inhibitors is thioridazine (TZ; see
Table 3). To be certain that the NDH-2 enzymes were the actual targets
of the inhibitors in the coupled assay with E. colimembranes, the same
experiments were repeated using10 mM Na-succinate in place ofTable 2
Inhibition of S. aureus NDH-2 activity by phenothiazines.
% of inhibition by 50 μM phenothiazines
NdhC NdhF
Quinones TPZ CPZ TPZ CPZ
Q8a 80 ± 10 87 ± 9 0 68 ± 7
DMNb 54 ± 6 73 ± 8 0 33 ± 5
Data are expressed as average ± SD of three independent experiments.
a Enzyme activitywasmeasured at 37 °C in the presence of 220 μg/ml E. coliΔnuoΔndh
membranes and 20 μM FAD.
b Enzyme activity wasmeasured at 37 °C in the presence of 125 μg/ml asolectin, 20 μM
FAD, 50 μM DMN and 0.05% dodecylmaltoside. The substrate concentrations used were
150 μM NADH for NdhC and 300 μM for NdhF.NADH as the electron source andmonitoring oxygen utilization. No inhi-
bitionwas observed, indicating that the phenothiazines (up to 50 μM)are
not inhibiting either E. coli succinate dehydrogenase or the E. coli respi-
ratory oxygen reductases.
3.4. The effects of phenothiazines on S. aureus membranes
Membranes of S. aureus were obtained from cells grown for 14 h at
37 °C, 200 rpm. The steady-state rate of respiration of S. aureus mem-
braneswas determined in a cell-free amperometric assay. NADHaddition
to the membranes (~200 μg/ml) results in the consumption of oxygen
that is fully inhibited by the addition of 50 μM of either TZ or TPZ
(Table 4). The IC50 for S. aureusmembranes with either drug, TZ or TPZ,
is similar to those obtained with the puriﬁed NdhC protein coupled to
E. coli respiratory chain (Tables 3 and 4). Since TPZ does not inhibit
NdhF, it is concluded that when S. aureus is grown under these con-
ditions, the NDH-2 present is predominantly NdhC. NADH-driven
respiration of membranes is mostly inhibited by the addition of 50 μM
TPZ (8±1 μmol O2mg−1 protein s−1), but is restored to the uninhibited
activity (659±28 μmol O2mg−1 protein s−1) by the addition of puriﬁed
NdhF (736 ± 30 μmol O2 mg−1 protein s−1), which reconstitutes with
the S. aureus membranes, feeding electrons to the menaquinone pool
and, from there, to the terminal oxygen reductases. The recovery of
oxygen consumption implies that the site of inhibition by phenothiazines
is upstream of the menaquinol-oxidases. Oxygen consumption was also
examined using other electron donors: 10 mM DL-lactate, 10 mMTable 4
Respiratory chain activity of S. aureusmembranes and its inhibition by phenothiazines.
Respiration activity
(μmol O2 mg−1 protein s−1)
IC50 (μM)
100 μM KCN TPZ TZ
NADH 659 ± 28 195 ± 10 18.5 ± 3 7.4 ± 1
DL-lactate 157 ± 15 158 ± 13 N.D. N.D.
Na-succinate 0 N.D. N.D. N.D.
DL-malate 0 N.D. N.D. N.D.
Data are expressed as average ± SD of at least three independent experiments.
N.D.: not determined.
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Fig. 3. Membrane potential, ATP/ADP ratios and respiration of S. aureus cells in the
presence of TZ. (A) Fluorescence of DisC3(5) plus S. aureus cells immediately after the ad-
dition of different TZ concentrations as indicated (AU, arbitrary units). (B) ATP/ADP ratios
of S. aureus cells after 10 (black bars) or 60 (white bars) min of incubation in the presence
of different TZ concentrations as indicated. Data are expressed as average ± standard de-
viation of three independent experiments. (C)Whole cell respirationwasmeasured in the
absence (closed symbols) or presence (opened symbols) of 1 μM CCCP and different TZ
concentrations as indicated. Data are representative of results of three separate
experiments.
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consumption activity with either succinate or malate, and oxidase
activity with DL-lactate was about 4-fold lower than with NADH. The
DL-lactate oxidase activity was not inhibited by the phenothiazines but
could be 75% inhibited by 2 mM KCN (Table 4).
The fact that the respiration is not completely inhibited by 2 mM
KCN suggests the presence of a cyanide-resistant cytochrome bd in the
S. aureusmembranes. This was conﬁrmed spectroscopically by obtaining
the NADH-reducedminus air-oxidized spectrum of S. aureusmembranes
(Fig. S4). Peaks were observed at 427 nm, 532 nm and 556 nm, which
could represent both b-type cytochromes, 444 nm and 603 nm,
corresponding to the aa3-type oxygen reductase, and a heme d peak at
632 nm [49,50]. Using NADH as electron donor, oxygen consumption
was inhibited 70% by the addition of 100 μM KCN. It is concluded that
when grown as described, the membranes of S. aureus contain both
the aa3-type and bd-type menaquinol oxidases (Fig. S4 and Table 4).
3.5. Collapse of the membrane potential and ATP depletion
It has been established that NDH-2 indirectly contributes to the
proton motive force in aerobic and hypoxic M. tuberculosis and that
thioridazine treatment of M. tuberculosis causes a collapse of the
membrane potential, resulting in a concomitant reduction of ATP levels
as well as an increase in the intracellular NADH/NAD+ ratio [51]. There-
fore, we investigated the effects of TZ treatment of S. aureus cells on the
membrane potential and ATP/ADP ratio (Fig. 3). Accumulation, leading
to ﬂuorescence quenching of the membrane-permeant cation DisC3(5)
was used to measure the transmembrane electrical potential of intact
cells in suspension. Controls to validate this method with S. aureus cells
were performed by adding either 3mMcyanide or 1 μMof the uncoupler
CCCP to the cell suspension. Each treatment resulted in the rapid collapse
of the membrane potential, indicated by an immediate increase of the
DisC3(5) ﬂuorescence intensity.
The addition of thioridazine to S. aureus cells also resulted in an im-
mediate increase in DisC3(5) ﬂuorescence, indicating collapse of the
membrane potential and release of the accumulated DisC3(5). The
concentration-dependence of this effect is shown in Fig. 3A. Depletion
of the ATP pool followed the collapse of the proton motive force, but
higher TZ concentrations and a long incubation time (60 min) were nec-
essary to observe a signiﬁcant change in the ATP/ADP ratios (Fig. 3B).
Inhibition of respiration of the cell suspension was also measured
(Fig. 3C) under the same conditions used tomeasure themembrane po-
tential. Surprisingly, in thepresence of 50 μMTZ,which results in a rapid
collapse of the membrane potential (Fig. 3A), there is virtually no inhi-
bition of cell respiration. Inhibition of aerobic respiration in intact cells
by TZ is observed only at concentrations well over 100 μM (Fig. 3C).
However, when the same experiment is repeated in the presence of
1 μM CCCP, an uncoupler of oxidative phosphorylation, the addition of
50 μM TZ is sufﬁcient to inhibit over 80% of aerobic respiration, which
is completely inhibited by 100 μMTZ. This suggests that the phenothia-
zine TZ is being actively pumped out of S. aureus cells by efﬂux pumps,
which are disabled by the presence of the protonophore CCCP. It is well
established that efﬂux pumps are an important contributing factor to
drug resistance in S. aureus [52]. When the efﬂux pumps are disabled,
the intracellular concentration of TZ increases to a point where respira-
tion byNdhC is inhibited. The data are consistentwith, but do not deﬁn-
itively prove that NdhC is responsible for virtually all of the aerobic
respiration by S. aureus under the growth conditions employed. Further
work will be needed to further examine this.
Thioridazine is a lipophilic weak acid with a pKa of 8.89 [53], and has
been shown to be a weak uncoupler of oxidative phosphorylation with
isolated rat liver mitochondria [54]. The uncoupler activity was con-
ﬁrmed by examining the effect of TZ on the energization of E. coli
inverted membrane vesicles. In this system, the active site for ATP hy-
drolysis by the F1Fo-ATP synthase is facing the external solution, as is
the site for succinate oxidation by succinate:quinone oxidoreductase(succinate dehydrogenase/complex II). The addition of either ATP or
succinate to the suspension of inverted membrane vesicles results in
active proton pumping into the vesicle, corresponding to what would
normally be proton pumping out of the cell. This leads to acidiﬁcation
of the small vesicle interior, and this acidiﬁcation is monitored by the
ﬂuorescent dye ACMA (9-amino-6-chloro-2-methoxy acridine) [55]
which is present in the solution. As observed in Fig. 4, the protonation
of ACMA inside the acidic vesicles results in accumulation of the dye
and, consequently, in ﬂuorescence quenching [55,56]. The addition of
an uncoupler (SF6847) or an inhibitor of respiration (KCN) or an inhibitor
of the ATP synthase (DCCD) results in collapse of the pH gradient across
themembrane and, consequently, the equilibration of the ACMA concen-
trations on the inside and outside of the vesicles (Fig. S5). As a result, a
rapid increase of theﬂuorescence fromACMA,which is no longer seques-
tered inside the vesicles, is observed. Fig. 4 shows that 3 μM TZ is sufﬁ-
cient to completely collapse the pH gradient in the inverted membrane
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Fig. 4.Denergization of invertedmembrane vesicles by TZ addition. Quenching of ACMA ﬂuorescence in invertedmembrane vesicles from E. coliwas observed after the addition of either
(A) ATP or (B) succinate. Different concentrations of the TZ compoundwere added after complete membrane energization. Data are representative of at least 3 independent experiments.
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respiration. As a complementary assay, Δψ was determined in the
presence of TZ and the known uncoupler SF6847 by using the ﬂuores-
cence dye Oxonol VI. Oxonol VI is an anionic slow-response probe,
which exhibits potential-dependent changes in its transmembranedistri-
bution that is accompanied by a ﬂuorescence change [57]. Fig. 5 shows
that the membrane potential is completely dissipated upon the addition
of 10 μM TZ. Hence, in addition to being an inhibitor of both of the
NDH-2 enzymes in S. aureus, TZ is also an uncoupler of oxidative phos-
phorylation as previously suggested [58].4. Discussion
The current work is inspired by the recent approval of the anti-TB
drug, TMC207, which inhibits the membrane-bound ATP synthase in
M. tuberculosis, leading to the depletion of energy that is necessary for
both the replicative as well as persistent states [15]. The ATP synthase
is driven by the proton motive force across the cytoplasmic membrane
which, in aerobic organisms, is driven by aerobic respiration. Hence,
drugs targeted to the aerobic respiratory chain should be considered,
particularly when pathogens have respiratory enzymes that are
distinctly different from those in the mitochondrion. This is the case
for the type-2 NADH dehydrogenase, or NDH-2, which is an important
respiratory component in a number of pathogens but not present in
the mammalian mitochondrial respiratory chain [14,16,18,19]. Indeed,
NDH-2 is actively being pursued as a possible drug target against
M. tuberculosis [14–17], P. falciparum [18] and T. gondii [13,19]. Although
NDH-2 is often present in organisms that also contain alternative NADH0.0 1.5 3.0 4.5 6.0
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Fig. 5.Quenching of Oxonol VIﬂuorescence in invertedmembrane vesicles in thepresence
of an uncoupler and TZ. Oxonol VI ﬂuorescence in invertedmembrane vesicles from E. coli
was quenched after the addition of NADH. Upon the addition of the uncoupler SF6847 and
TZ the Oxonol VI ﬂuorescence increased due to a dissipation of the membrane potential.
Data are representative of at least 3 independent experiments.oxidizing respiratory enzymes, either Complex I or the sodium-
pumping NADH:quinone oxidoreductase, in some pathogens, NDH-2
is the only respiratory NADH dehydrogenase present. This is the case
for S. aureus, whose genome encodes two putative NDH-2s. It is very
likely that the function of at least one of the NDH-2s will be essential
for S. aureus to survive under conditionswhere it relies on energy produc-
tion from either aerobic or anaerobic (e.g., nitrate) respiration. It was re-
cently reported that aerobic respiration is required for full S. aureus
pathogenesis [59]. Strains of S. aureus that are unable to synthesize
menaquinone and/or heme, although unable to respire, can survive by
fermentation in a near dormant state. These respiration-impaired SCVs
(small colony variants) are etiological agents of persistent infections
[59]. It is not clear whether the inhibition of both NDH-2s in S. aureus
would impact the survival of these small colony variants.
4.1. Two S. aureus NDH-2s
Wehave shown that each of the twogenes annotated as NDH-2 in the
S. aureus genome does encode an authentic NDH-2, denoted NdhC and
NdhF. Both enzymes were produced by heterologous gene expression
in E. coli and were shown to oxidize NADH and reduce a variety of qui-
nones. The steady state kinetic parameters (Table 1) are different for
the two enzymes though the physiological consequences are not
known. Under the growth conditions employed in this work, NdhC
appears to be the dominant NDH-2 present in S. aureus membranes,
and this enzyme has a 6-fold higher kcat with DMN as the electron ac-
ceptor and 4-fold lower KM for NADH than NdhF. The kcat of NdhC
(1500 NADH s−1) is substantially higher than those reported for
NDH-2s isolated from other bacterial sources. For example, E. coli has
an kcat of ~18 NADH s−1 [8,10], M. tuberculosis of ~10 NADH s−1 [27],
Bacillus pseudoﬁrmus of ~39 NADH s−1 [60], Thermus thermophilus of
~1 NADH s−1 [45], Gluconobacter oxydans of ~9 NADH s−1 [61], and Co-
rynebacterium glutamicum of ~213 NADH s−1 [62].
4.2. The red color of NdhF
Conditions under which NdhF would be present in the S. aureus
membrane are not known. Compared to a regular ﬂavoprotein spectrum
[42], the oxidized form of puriﬁed NdhF has an unusual red color due to
an absorbance band at about 550 nm. This absorbance is similar to what
has been reported for ﬂavoprotein disulﬁde reductases [63,64] and has
been ascribed, in the AhpF protein [65], to a thiolate-FAD charge transfer
band arising from the interaction with a cysteine near the C4a position of
the ﬂavin ring. This is likely also the case for NdhF, which contains 3 Cys.
4.3. A new assay for NDH-2
Because NDH-2 normally functions on the surface of a membrane
bilayer using long-chain quinones as substrate, an assay was developed
Table 5
MIC for the growth of S. aureus by phenothiazines.
Phenothiazine MIC (μM)
TZ 70 ± 9
TPZ 70 ± 10
CPZ 170 ± 15
Data are expressed as average ± SD of four independent
experiments. TheMIC is the lowest concentration of the com-
pound required to eliminate visible growth in liquid culture
under conditions described in the text.
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S. aureus are readily reconstitutedwith E. colimembranes and efﬁciently
deliver electrons to the quinone pool, resulting in aerobic respiration.
The addition of FAD to the reaction mix increases the reconstituted
NADH oxidase activity, indicating that the FAD is incorporated to that
portion of the recombinant protein which is puriﬁed without bound ﬂa-
vin thereby restoring activity. This assay avoids possible artifacts that
might arise from the use of soluble quinone analogues, and can be used
to better evaluate hydrophobic inhibitors. The success of this assay also
implies that the two S. aureus NDH-2 enzymes do not require S. aureus
phospholipids to bind to themembrane. Furthermore, this assay demon-
strates that both enzymes can use long chain ubiquinone-8 (dominant in
aerobically grown E. coli) aswell asmenaquinone-8 (present in S. aureus)
as the electron acceptor. Membranes from E. coli were used rather than
from S. aureus because of the availability of E. coli strains lacking endoge-
nous membrane-bound NADH oxidase activity. The reconstitution also
works with S. aureusmembranes, but one needs to subtract a substantial
background activity due to the presence of the NDH-2 enzymes in the
membranes.
4.4. Phenothiazines inhibit both S. aureus NDH-2 enzymes
Phenothiazines are used in the clinic as neuroleptic antipsychotic
drugs, but are also known to have antimicrobial activities [28,66,67].
Although they cause signiﬁcant side effects, phenothiazines may offer a
potential therapeutic use in problematic infections caused by antibiotic-
resistant bacteria, particularly in combination with other antibiotics
[68–70]. Phenothiazines inhibitM. tuberculosisNDH-2, which is a key en-
zyme in the M. tuberculosis respiratory chain [14,17,24,27], consistent
with the transcriptional proﬁle analysis which indicates that they act as
respiratory poisons [71]. In the current work, it is shown that phenothia-
zines also inhibit the NDH-2 enzymes present in S. aureus, with the most
potent being thioridazine, which inhibits both NdhC (IC50 = 8 μM) and
NdhF (IC50 = 14 μM). This demonstrates that it is possible to obtain
drugs that block both of these enzymes, enhancing the likelihood that
drugs based on NDH-2 as a target could be therapeutically effective.
4.5. Phenothiazines are also uncouplers of oxidative phosphorylation
Although phenothiazines are effective inhibitors of the NDH-2
enzymes in vitro, they are not effective inhibitors with intact cells
because the drugs are pumped out by efﬂux pumps. This is demonstrated
by showing that the presence of 1 μM CCCP, a protonophore uncoupler
which collapses the proton motive force, substantially increases the efﬁ-
cacy of thioridazine to inhibit cellular respiration (Fig. 3C). Thioridazine
must be pumped out by one or more efﬂux pumps that are driven by
the proton motive force.
Phenothiazines themselves are known to inhibit the function of some
of the energy-dependent efﬂux pumps from Mycobacterial species, in-
cludingM. tuberculosis [69,72], as well as S. aureus efﬂux pumps [52,58,
73]. For this reason, phenothiazines can be used to reverse the resistance
to other antibiotics [69,72]. Thioridazine (TZ; Table 3), which is less toxic
to humans than chlorpromazine [74], can be used in combination with
other antibiotics (e.g., oxacillin) to kill MRSA as well asM. tuberculosis at
concentrations that are tolerable in humans and can be clinically applied
[58,75,76].
At least 14 efﬂux pumps have been described for S. aureus [52], and
they are involved in several physiological processes, such as cell wall
division, the maintenance of pH homeostasis and secretion of intracel-
lular metabolites [77]. These pumps are driven either directly by ATP
hydrolysis or by proton-ﬂux under the control of the proton motive
force [52,78,79]. The mechanism of inhibition may involve direct inter-
actions with speciﬁc efﬂux pump proteins or may depend in part on
reducing the magnitude of the proton motive force, and may be strain
dependent [58].The current work demonstrates that the addition of 50 μM TZ to a
suspension of S. aureus cells, under the conditions assayed, results in
the collapse of the membrane potential, which will rapidly stop from
functioning any of the efﬂux pumps that rely directly on the proton
motive force. The concentrations of phenothiazines necessary to inhibit
the growth of S. aureus are in the same range needed to collapse the
membrane potential. The reported MIC values for inhibition of growth
by TZ and TPZ are 40–60 μM and that by CPZ is 90–125 μM [28,80].
The MIC values obtained in the current work are somewhat higher
(Table 5) but still in the range of concentrations required for 100% col-
lapse of the membrane potential (Fig. 3A). As previously recognized,
the inactivation of efﬂux pumps would explain the fact that phenothia-
zines synergize with other antibiotics by reducing the rate at which
they are being pumped out of the cell [58]. The current demonstration
of the uncoupling activity of phenothiazines is also consistent with a
previous report that phenothiazines act as modest uncouplers of
isolated rat liver mitochondria [54]. Mitochondrial uncoupling may re-
late to both the therapeutic mode of action of phenothiazines as well
as their toxicity.
It is paradoxical that although 50 μM TZ is sufﬁcient to collapse the
membrane potential, the intracellular concentration does not get high
enough to inhibit cell respiration, whereas the presence of 1 μM CCCP
allows TZ to accumulate in cells to the extent that 50 μMTZ largely elim-
inates cell respiration (Fig. 3). This can be explained if TZ is acting as a
protonophore and the protonated, cationic form is the major current
carrier across the cell membrane in response to the active proton
pumps. The uncoupling mechanism requires that the neutral form of
the uncoupler cross the membrane in the opposite direction (inside to
outside) of the protonated form. The steady state intracellular concen-
tration of the uncoupler will depend on the rates of the multiple kinetic
steps involved. It is feasible that even under the steady state conditions
where the cyclic ﬂux of TZ is sufﬁcient to collapse themembrane poten-
tial, the intracellular TZ concentration will not be sufﬁciently high to in-
hibit the NDH-2 enzymes. If, on the other hand, CCCP is also present,
then CCCP becomes the dominant current carrier, collapsing the proton
motive force, and the TZ can accumulate due to the absence of the func-
tional efﬂux pumps. Whether this speculation is correct will require ad-
ditional studies on the mechanism by which the phenothiazines appear
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